Saturday 17 October 2026 Export CYTOF’s income statement to Excel — free account

Altamira Therapeutics Ltd.

CYTOF Healthcare Biotechnology

Altamira Therapeutics Ltd.’s revenue for fiscal 2022 (year ended December 2022) was $320,300.00.

0.09 0.00 0.00%

Follow CYTOF

Alert me

Market cap: $1.1M
P/E: 0.0×
Fwd P/E: −0.6×
Dividend yield: —
F-score: n/a
Altman Z: −60.32
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 1.13

Revenue —

Net Income (12.73)

Free Cash Flow (10.72)

Net Debt 0.43

Current Ratio 0.11

Debt/Equity 0.11

P/E ratio 0.00

Fwd P/E (0.57)

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 65.40%

Next Y EPS Growth 55.90%

Next Y revenue growth (100.00%)

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2022	2023	2024	2025
Cash	0	1	1	0
Receivables	1	0	0	0
Inventory	0	—	—	—
Other	—	—	—	—
	2	1	2	0

	2022	2023	2024	2025
Payables	5	1	1	2
ST’ Debt	6	—	—	1
Other	—	—	—	0
	13	1	1	4

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(23.57%)	(29.81%)	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’22	—	—	—	—	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	(1)	—	—	(2)
’24	—	(3)	—	—	(6)
’23	—	—	—	—	(13)
’22	—	—	—	—	(9)
’21	—	—	—	—	(15)
’20	—	—	—	—	(5)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	(1)	—	—	(2)
’24	—	(3)	—	—	(6)
’23	—	(9)	—	—	(13)
’22	—	(2)	—	—	(11)
’21	—	(2)	—	(9)	(19)
’20	—	(2)	—	(4)	(8)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	(0.55)
’24	—	—	—	—	(2.99)
’23	—	—	—	—	(8.77)
’22	—	—	—	—	(610.60)
’21	—	—	—	—	(572.00)
’20	—	—	—	—	(580.00)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	67,200.00	30,400.00	1,840.00	520.00	260.00	484.00	79.02	1.88	0.07	0.05	Analyst estimates 2026–2028 Powerpack
	High	636,800.00	111,200.00	52,000.00	4,360.00	2,640.00	2,500.00	860.00	119.40	3.60	0.20
People
People	Employees	24	24	11	12	9	17	18	12	13	—
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.00	0.00	—
Income, $m
Income, $m	Revenue	—	—	—	—	—	0	0	—	—	—
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	(3,407.01)	(372.40)	—	—	—
	EBT	(31)	(25)	(12)	(7)	(9)	(19)	(28)	(8)	(8)	(3)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	(27,185.84)	(8,682.49)	0.00	0.00	0.00
	Net income	(31)	(25)	(12)	(7)	(9)	(19)	(28)	(4)	(8)	(3)
	Depreciation	0	0	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	2.11	7.04	0.00	0.00	0.00
	Earnings	(72,000.00)	(45,520.00)	(5,920.00)	(920.00)	(580.00)	(572.00)	(610.60)	(8.77)	(2.70)	(0.55)
	Cash flow	(74,760.75)	(49,343.00)	(6,764.30)	(1,157.26)	(344.40)	(451.94)	(199.98)	(26.09)	(2.16)	(0.37)
	Capex	(620.25)	(311.00)	(931.90)	(416.19)	(164.63)	(109.94)	(49.35)	0.00	(0.04)	0.01
	Free cash flow	(75,381.00)	(49,654.00)	(7,696.20)	(1,573.45)	(509.03)	(561.88)	(249.33)	(26.09)	(2.20)	(0.37)
	Book value	35,898.00	(4,395.00)	1,865.70	832.25	1,192.45	419.94	(191.50)	15.63	2.32	0.57
	Shares, m	0	0	0	0	0	0	0	0	3	5
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	0.00	0.00	—	—	—
	P/S	—	—	—	—	—	0.00	0.00	—	—	—
	P/B	—	—	—	—	—	0.10	0.03	—	—	—
	EV/Sales	—	—	—	—	—	0.00	0.00	—	—	—
	EV/FCF	—	—	—	—	—	(0.21)	(0.32)	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(30)	(25)	(14)	(8)	(5)	(15)	(9)	(13)	(6)	(2)
	Capex	0	0	(2)	(3)	(2)	(4)	(2)	—	0	0
	Free cash flow	(30)	(25)	(15)	(11)	(8)	(19)	(11)	(13)	(6)	(2)
Balance, $m
Balance, $m	Working capital	25	6	2	0	9	(1)	(12)	0	0	(4)
	Total debt	13	10	1	—	1	0	6	—	—	1
	Net debt	(20)	(5)	(4)	(2)	(11)	(1)	6	(1)	(1)	1
	Shareholders’ equity	14	(2)	4	6	18	14	(9)	8	7	3
Returns, %
Returns, %	ROA	(69.89)	(91.34)	(83.32)	(68.87)	(55.58)	(88.92)	(204.28)	(54.69)	(95.05)	(35.73)
	ROIC	0.00	0.00	0.00	(102.37)	(54.71)	(90.30)	0.00	(61.90)	(76.92)	(66.25)
	ROE	(105.24)	(407.96)	(1,532.55)	(136.13)	(73.00)	(119.71)	(1,071.90)	829.81	(118.79)	(61.66)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2022 · latest quarter Jan 0001 · fundamentals updated 14 Oct 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MLEC Moolec Science SA	$1.4M	— (loss-making)	— (loss-making)	+948.39% (above 0%: growing)	n/m	+4.48% (above 0%: growing)	(25.52%)	(77.92%)	Compare
PTIX Atrinsic Inc.	$1.3M	0.3×	—	+34.31% (above 0%: growing)	n/m	+46.07% (above 0%: growing)	0.00%	0.00%	Compare
SPRC SciSparc Ltd.	$1.2M	— (loss-making)	7.9×	—	n/m	+14.95% (above 0%: growing)	35.75%	0.00%	Compare
CYTOF Altamira Therapeutics Ltd.	$1.1M	— (loss-making)	— (loss-making)	—	n/m	+85.35% (above 0%: growing)	(157.79%)	0.00%
BBLG Bone Biologics Corp.	$1.1M	— (loss-making)	—	—	n/m	−12.97% (below 0%: shrinking)	—	0.00%	Compare
BPTH Bio-Path Holdings, Inc.	$1.1M	— (loss-making)	— (loss-making)	—	n/m	+98.68% (above 0%: growing)	0.00%	0.00%	Compare
CRIS Curis, Inc.	$1.1M	— (loss-making)	— (loss-making)	−65.98% (below 0%: shrinking)	n/m	−20.44% (below 0%: shrinking)	100.00%	0.00%	Compare
MNTRQ 9 Meters Biopharma, Inc.	$1.0M	— (loss-making)	—	−25.99% (below 0%: shrinking)	n/m	+0.01% (above 0%: growing)	0.00%	0.00%	Compare
ZVSA ZyVersa Therapeutics, Inc.	$970.0K	— (loss-making)	—	—	n/m	+54.91% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$1.1M	—	—	+4.16%	—	+9.72%	0.00%	0.00%

All 614 Biotechnology stocks →